Pivotal Phase 3 Study on Primary Hyperoxaluria Has High Quality Results
As seen in PR Newswire, researchers at the biopharmaceutical company OxThera AB have spent 52 weeks studying 25 patients with primary hyperoxaluria (PH), a rare disease that progressively damages the…